cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Allovir Inc
6 own
5 watching
Current Price
$0.73
$-0.03
(-4.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
86.3M
52-Week High
52-Week High
5.33000
52-Week Low
52-Week Low
0.58000
Average Volume
Average Volume
0.57M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization86.3M
icon52-Week High5.33000
icon52-Week Low0.58000
iconAverage Volume0.57M
iconDividend Yield--
iconP/E Ratio--
What does the Allovir Inc do?
We are a leading late clinical-stage cell therapy company developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. Our innovative and proprietary virus-specific T cell, or VST, therapy platform allows us to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. --- We were formed in August 2013 under the laws of the state of Delaware under the name AdCyte LLC. In July 2014, we changed our name to ViraCyte LLC. In September 2018, we converted from a Delaware limited liability company to a Delaware corporation and changed our name to ViraCyte, Inc. In May 2019, we changed our name to AlloVir, Inc. Our principal executive offices are located at 139 Main Street, Suite 500, Cambridge, MA 02142, and our phone number is 617-433-2605. We have three wholly-owned subsidiaries, AlloVir International Designated Activity Company, AlloVir Securities Corporation and AlloVir Italia S.R.L., each of which was formed in 2019. Our website address is www.AlloVir.com.
Read More
How much money does Allovir Inc make?
News & Events about Allovir Inc.
Business Wire
12 months ago
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.75 per share. The gross proceeds to AlloVir from the offering, before deducting...
TipRanks Financial Blog
1 year ago
Morgan Stanley analyst Michael Ulz maintained a Buy rating on AlloVir (ALVR Research Report) yesterday and set a price target of $20.00. The comp... Morgan Stanley analyst Michael Ulz maintained a Buy rating on AlloVir (ALVR Research R...
Business Wire
1 year ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced the companys 2023 priorities and anticipated future milestones across its pipeline of virus-specific T cell therapies, including its lead investigational therapy posoleucel. These updates...
Business Wire
1 year ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that final data from the Phase 2 study of posoleucel for the prevention of clinically significant infections or diseases by multiple viruses following allogeneic hematopoietic cell...
Business Wire
2years ago
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, for the treatment of BK...
Frequently Asked Questions
Frequently Asked Questions
What is Allovir Inc share price today?
plus_minus_icon
Can Indians buy Allovir Inc shares?
plus_minus_icon
How can I buy Allovir Inc shares from India?
plus_minus_icon
Can Fractional shares of Allovir Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Allovir Inc stocks?
plus_minus_icon
What is today’s traded volume of Allovir Inc?
plus_minus_icon
What is today’s market capitalisation of Allovir Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Allovir Inc?
plus_minus_icon
What percentage is Allovir Inc down from its 52-Week High?
plus_minus_icon
What percentage is Allovir Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.73
$-0.03
(-4.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00